Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05790655 · ClinicalTrials.gov registry record · NA
Ovarian PRP for Diminished Ovarian Reserve
A NA study of Diminished Ovarian Reserve, sponsored by Generation Next Fertility.
- Recruiting
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT05790655 is a NA study of Diminished Ovarian Reserve that is actively recruiting participants, run by Generation Next Fertility. The registered enrollment target is 230 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05790655, a NA study of Diminished Ovarian Reserve, is actively recruiting participants, sponsored by Generation Next Fertility.
- RECRUITING
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.
Conditions Studied
Interventions
- OTHER oPRP
- OTHER Placebo- Serum
Study Locations (1)
New York
- Generation Next Fertility - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-10-07 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05790655
The ClinicalTrials.gov registry entry for NCT05790655 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Generation Next Fertility, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diminished Ovarian Reserve appearing as the primary indexed condition, and to 2 interventions - of which oPRP is the first listed.
NCT05790655 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05790655 about?
NCT05790655 is a clinical study titled "Ovarian PRP for Diminished Ovarian Reserve". This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of p...
What is the current status of trial NCT05790655?
This trial is currently recruiting. It is a NA study. The enrollment target is 230 participants. The study started on 2023-10-07. Estimated completion is 2025-12-31.
What conditions does trial NCT05790655 study?
This clinical trial studies the following conditions: Diminished Ovarian Reserve.
What interventions are being tested in trial NCT05790655?
The interventions under investigation include: oPRP (OTHER), Placebo- Serum (OTHER).
Who is sponsoring clinical trial NCT05790655?
This trial is sponsored by Generation Next Fertility, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05790655 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diminished Ovarian Reserve
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.